88390-32-3

Usage

InChI:InChI=1/C5H13NO/c1-5(4-7)2-3-6/h5,7H,2-4,6H2,1H3/t5-/m1/s1

Upstream product

• 201230-82-2 carbon monoxide 
• 109-75-1 but-3-enenitrile 
• 96192-37-9 (R)-2MeGABA 
• 42453-21-4 4-Amino-2-methylbutyric acid 
• 78-92-2 iso-butanol 
• 13931-35-6 4-(Tetrahydro[2H]pyran-2-yloxy)-3-methyl-2-butenenitrile 
• 63987-58-6 rac-2-methyl-4-phthalimidobutanoic acid 
• 63987-58-6 (R)-2-methyl-4-phthalimido-butyric acid 
• 73616-96-3 (S)-4-hydroxy-3-methyl-butyronitrile 

Downstream Products

• 1392843-27-4 C₇H₁₃NO₃ 
• 1392843-04-7 C₁₅H₂₉NO₃ 
• 404849-99-6 C₉H₁₇NO₃ 
• 183551-55-5 (R)-4-amino-2-methyl-1-butanol tetrahydropyranyl ether 
• 1392843-19-4 C₇H₁₃NO₃ 
• 1392842-92-0 C₁₅H₂₉NO₃ 
• 404849-98-5 C₉H₁₇NO₃ 
• 1437-87-2 4-Amino-2-methyl-butylhydrogensulfat 
• 1415219-11-2 1,3-dimethyl-1-propylpyrrolidinium bis(trifluoromethanesulfonyl)amide 
• 1334541-31-9 di-tert-butyl (4-hydroxy-3-methylbutyl)imidodicarbonate 
• 1334541-30-8 di-tert-butyl (3-methyl-4-oxobutyl)imidodicarbonate 
• 1334541-32-0 methyl (2E)-6-[bis(tert-butoxycarbonyl)amino]-2-bromo-4-methylhex-2-enoate 
• 1334541-33-1 methyl (2Z)-6-[bis(tert-butoxycarbonyl)amino]-4-methyl-2-(1-phenyl-1H-imidazol-4-yl)hex-2-enoate 

Relevant academic research and scientific papers

APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS AND USES THEREOF

Described herein are ASK1 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of blood disease, autoimmune disorders, pulmonary disorders, hypertension, inflammatory diseases, fibrotic diseases, diabetes, diabetic nephropathy, renal diseases, respiratory diseases, cardiovascular diseases, acute lung injuries, acute or chronic liver diseases, and neurodegenerative diseases.

Biosynthetically intriguing chlorinated lipophilic metabolites from geographically distant tropical marine cyanobacteria

Five new vinylchlorine-containing metabolites, the lipoamides janthielamide A and kimbeamides A-C and the ketide-extended pyranone kimbelactone A, have been isolated from collections of marine cyanobacteria made in Curacao and Papua New Guinea. Both janthielamide A and kimbeamide A exhibited moderate sodium channel blocking activity in murine Neuro-2a cells. Consistent with this activity, janthielamide A was also found to antagonize veratridine-induced sodium influx in murine cerebrocortical neurons. These lipoamides represent the newest additions to a relatively rare family of marine cyanobacterial-derived lipoamides and a new structural class of compounds exhibiting neuromodulatory activities from marine cyanobacteria.

Synthesis and application of a new bisphosphite ligand collection for asymmetric hydroformylation of allyl cyanide

A series of mono- and bidentate phosphites was prepared with (S)-5,5',6,6'-tetramethyl-3,3'-di-tertbutyl-1,1'-biphenyl-2,2'-dioxy [(S)-BIPHEN] as a chiral auxiliary and screened in the asymmetric hydroformylation of allyl cyanide. These hydroformylation results were compared with those of two existing chiral ligands, Chiraphite and BINAPHOS, whose utility in asymmetric hydroformylation has been previously demonstrated. Bisphosphite 11 with a 2,2'-biphenol bridge was found to be the best overall ligand for asymmetric hydroformylation of allyl cyanide with up to 80% ee and regioselectivities (branch-to-linear ratio, b/l) of 20 with turnover frequency of 625 [h-1] at 35 °C. BINAPHOS gave enantioselectivities up to 77% ee when the reaction was conducted in either acetone or neat but with poor regioselectivity (b/l 2.8) and activities 7 times lower than that of 11. The product of allyl cyanide hydroformylation using (R,R)-11 was subsequently transformed into (R)-2-methyl-4-aminobutanol, a useful chiral building block. Single-crystal X-ray structures of (S,S)-11 and its rhodium complex 19 were determined.

PROCESS FOR PRODUCING OPTICALLY ACTIVE AMINOALCOHOL

An industrially advantageous process for producing optically active 4-amino-2-methylbutane-1-ol which is useful as an intermediate in synthesizing optically active medicines and pesticides. Racemic 4-amino-2-methylbutane-1-ol is treated with an optically active organic acid. The diastereomeric salt thus obtained is crystallized out and subjected to solid-liquid separation to give optically active 4-amino-2-methylbutane-1-ol. The diastereomeric salt of optically active 4-amino-2-methylbutane-1-ol with an optically active reagent for optical resolution is decomposed by bringing into contact with a solvent and an alkali and subjected to solid-liquid separation, thereby recovering the optically active 4-amino-2-methylbutane-1-ol from the filtrate. Further, the filtration residue containing the alkali salt of the reagent for optical resolution obtained by the solid-liquid separation is brought into contact with a solvent and an acid. Then the reagent for optical resolution thus crystallized out is subjected to solid-liquid separation and recovered.

Process for the preparation of trans-3-formylbut-2-enenitrile

A process is provided for the preparation of trans-3-formylbut-2-enenitrile (V), a key intermediate in the synthetic pathway leading to trans-zeatin (I) and dihydrozeatin (II), both of which are naturally occurring cytokinins. The process involves a base catalyzed condensation of a dialkyl or cyclic acetal of pyruvaldehyde (III) with acetonitrile to yield the corresponding dialkyl or cyclic acetal of 3-formylbut-2-enenitrile (IV). The reaction proceeds regioselectively to form the favored trans-isomer in good yield. The α,β-unsaturated nitrile thus formed is hydrolyzed under acidic conditions to yield trans-3-formylbut-2-enenitrile (V), which can be easily distilled without contamination of the cis-isomer. The trans-3-formylbut-2-enenitrile can be selectively or exhaustively reduced to form either trans-3-hydroxymethylbut-2-enylamine (VI) or 3-hydroxymethylbutylamine (VII), which compounds can be condensed with 6-chloropurine (IX) by known methods to form trans-zeatin or dihydrozeatin respectively.